{"id":"a20476b2-994c-4fba-a189-382fce9c9c3c","name":"Rex Bionics","slug":"rex-bionics","description":"Rex Bionics develops the [REX](/models/rex-bionics-rex) robotic exoskeleton, a hands-free, self-supporting mobility device that enables wheelchair users with spinal cord injury and other neurological conditions to stand, walk, and exercise. Founded in Auckland in 2003, the company pioneered Robot-Assisted Physiotherapy (RAP) and ran the RAPPER II clinical trial across leading neuro-rehabilitation clinics in the UK and Australia. Rex Bionics was admitted to trading on the London Stock Exchange's AIM in 2014 under the ticker RXB.","status":"private","founded":2003,"hq":"Auckland, New Zealand","hqLat":-36.852095,"hqLng":174.7631803,"hqGeocodedAt":"2026-08-05T14:45:29.312Z","hqAddress":null,"hqPrecision":null,"website":"rexbionics.com","fundingTotal":"17000000","type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":81,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://newatlas.com/rex-robotic-exoskeleton/15736/","title":"REX robotic exoskeleton","sourceName":"New Atlas"},{"url":"https://www.rexbionics.com/","title":"Rex Bionics (official)","sourceName":"Rex Bionics (primary)"},{"url":"https://exoskeletonreport.com/2015/05/rex-bionics-new-applications-and-markets/","label":"Rex Bionics: New Applications and Markets","title":"Rex Bionics: New Applications and Markets","mediaType":"article","sourceName":"Exoskeleton Report"},{"url":"https://biosciencemanagers.com/rxb-trading-update/","label":"RXB – Trading Update","title":"RXB – Trading Update","mediaType":"article","sourceName":"BioScience Managers"}],"keyFacts":[{"label":"Founders","value":"Richard Little, Robert Irving"},{"label":"CEO","value":"Crispin Simon (as of 2016)"},{"label":"CFO","value":"Peter Worrall (as of 2016)"},{"label":"Ticker","value":"AIM:RXB (admitted 2014)"},{"label":"FDA status","value":"REX not registered for at-home use in the US (as of 2016)"},{"label":"Distribution","value":"EnableMe (US), MAAB (China), Deltason (HK/Taiwan)"}],"aliases":["Rex Bionics"],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":"RXB","stockExchange":"AIM (London)","secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-06T03:10:00.348Z","updatedAt":"2026-08-21T22:25:24.228Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/rex-bionics","url":"https://registry.deploy.report/companies/rex-bionics","name":"Rex Bionics","alternateName":["Rex Bionics"],"description":"Rex Bionics develops the [REX](/models/rex-bionics-rex) robotic exoskeleton, a hands-free, self-supporting mobility device that enables wheelchair users with spinal cord injury and other neurological conditions to stand, walk, and exercise. Founded in Auckland in 2003, the company pioneered Robot-Assisted Physiotherapy (RAP) and ran the RAPPER II clinical trial across leading neuro-rehabilitation clinics in the UK and Australia. Rex Bionics was admitted to trading on the London Stock Exchange's AIM in 2014 under the ticker RXB.","identifier":"a20476b2-994c-4fba-a189-382fce9c9c3c","foundingDate":"2003","address":"Auckland, New Zealand","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":4,"primary_source_types":[]}}}